A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Recruiting · Phase 1 · NCT07204418
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $16,981
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 56
About the trial
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Tested
- Xanomeline/ Trospium Chloride (drug)
- Dates
- Started 2025-10-13; completion 2026-12-03
- Results posted
- Not yet
The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $16,981 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Peter J. Winkle, MD Gastroenterology · Cypress, CA
- Patrick D. Yao, DO Family Medicine · Olathe, KS
- Cassandra C. Key, M.D. Internal Medicine · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials $6,870
- Icon Development Solutions $5,271
- Pra Health Sciences- Lenexa $4,840
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.